Publication Month: Dec 2021 | Report Code: TIPRE00016709 | No. of Pages: 188 | Category: Medical Device | Status: Published
Hemostasis analyzers provide a quick and easy measurement of blood platelet levels. A coagulation test could help detect and prevent blood clots that could cause a heart attack. A coagulation analyzer can measure the speed of the coagulation pathway and the amounts of thrombolin and thromboplastin in less than a few minutes.Cardiovascular diseases (CVDs) are likely to remain the most significant cause of morbidity and mortality worldwide. The CVDs are disorders of the heart and blood vessels and include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and other conditions. Some lifestyle-related issues that lead to cardiovascular diseases and difficulties are tobacco use, unhealthy diet, and physical inactivity. They increase the risk of heart attacks and strokes. Other risk factors for cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels. According to the World Health Organization (WHO), cardiovascular diseases are the number one cause of death globally.
|Market Size Value in||US$ 3,440.66 million in 2021|
|Market Size Value by||US$ 6,490.24 million by 2028|
|Growth rate||CAGR of 9.5% from 2021 to 2028.|
|No. of Pages||188|
|No. of Tables||111|
|No. of Charts & Figures||77|
|Historical data available||Yes|
|Segments covered||Product Type, Test, and End User|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Get more information on this report :
Older people are prone to heart diseases due to weak immunity and other health problems. General aging factors lead to stiffening heart and blood vessels that result in heart disorders. As the age grows, the systolic blood pressure also rises, leading to cardiovascular diseases (CVDs). Thus, in people aged 75 years and above, high blood pressure is a common risk factor for heart conditions. Coronary artery disease and heart failure are the others. Although the incidence of arrhythmias encompasses people of all age groups, it is rising significantly among the geriatric population.
According to the Global Ageing 2019 survey, the world's population of 65 years and above totaled 703 million in 2019. The senior demographic is expected to double to 1.5 billion people by 2050. The frequency of one person with age 65 or more is likely to increase from 1 in every 11 inhabitants in 2019 to 1 in every 6 inhabitants by 2025. This demographic is more susceptible to CVDs, such as arrhythmias. Similarly, according to the World Health Organization (WHO), the percentage of people aged 60 and above is estimated to reach 22% by 2050 from 12% in 2015. As per the report "Older Americans 2016: Key Indicators of Well-Being" by the Federal Interagency Forum on Aging-Related Statistics, 35.8% of individuals aged 85 and above had a mild or extreme cognitive disorder. Moreover, according to the United Nation's World Population Ageing 2017 report, in 2017, 962 million people were aged 60 years or over worldwide, and the number is expected to reach nearly 2.1 billion by 2050.
The elderly population is more prone to atypical presentations, comorbid conditions, and unfavorable outcomes. The primary reason for the diseases is related to the structural and functional changes in the cardiovascular system associated with aging. The rise in the global geriatric population is leading to a surge in cardiovascular diseases, which, in turn, is propelling the demand for hemostasis analyzers
Based on product type, the hemostasis analyzers market is further segmented into laboratory analyzers and point-of-care testing systems. In 2021, the laboratory analyzers segment is held the largest share of the market, and the point-of-care testing systems segment is estimated to register the highest CAGR during 2021–2028.
Get more information on this report :
Based on test, the market is segmented into activated partial thromboplastin time, D-Dimer test, fibrinogen test, prothrombin time test, and others. In 2021, the activated partial thromboplastin time segment held the largest share of the market. The prothrombin time test segment is expected to register the highest CAGR in the market during 2021–2028.
Based on end users, the market is segmented into hospitals/clinics, independent diagnostic laboratories, home care settings, and others. In 2021, the hospitals/clinics segment accounted for the largest share of the market. The independent diagnostic laboratories segment is expected to register the highest CAGR in the market during 2021–2028.
Companies operating in the hemostasis analyzers market emphasize adopting the strategy of product innovations to meet the evolving customer demands worldwide, which also permits them to maintain their brand name in the global market.
The Hemostasis Analyzers market is segmented based on product type, test, and end-user. Based on product type, the hemostasis analyzers market is segmented into laboratory analyzers and point-of-care testing systems. Based on test, the market is further segmented into activated partial thromboplastin time, D-Dimer test, fibrinogen test, prothrombin time test, and others. Based on end-user, the market is segmented into hospitals/clinics, independent diagnostic laboratories, home care settings, and others. In terms of geography, the hemostasis analyzers market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, India, Japan, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM)